002317.SZ
Guangdong Zhongsheng Pharmaceutical Co., Ltd. [002317.SZ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
002317.SZ Stock Summary
Top 10 Correlated ETFs
002317.SZ
Top 10 Correlated Stocks
002317.SZ
In the News
002317.SZ Financial details
Company Rating
Buy
Market Cap
13.07B
Income
352.81M
Revenue
2.76B
Book val./share
5.08
Cash/share
2.28
Dividend
0.2
Dividend %
1.38%
Employees
1.64K
Optionable
No
Shortable
Yes
Earnings
23 Apr 2024
P/E
35.45
Forward P/E
-
PEG
16.65
P/S
4.58
P/B
2.86
P/C
6.32
P/FCF
-1145.02
Quick Ratio
3.33
Current Ratio
4.31
Debt / Equity
0.16
LT Debt / Equity
0.02
-
-
EPS (TTM)
0.42
EPS next Y
-
EPS next Q
-
EPS this Y
14.29%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-5.83%
Revenue last 5Y
2.53%
Revenue Q/Q
-19.92%
EPS Q/Q
0.86%
-
-
-
-
SMA20
-11.76%
SMA50
7.14%
SMA100
-11.76%
Inst Own
-
Inst Trans
-
ROA
5%
ROE
9%
ROC
0.07%
Gross Margin
61%
Oper. Margin
14%
Profit Margin
13%
Payout
49%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
10.22-22.8
52W High
-34.5%
52W Low
+44.1%
RSI
40
Rel Volume
0.44
Avg Volume
31.57M
Volume
13.97M
Perf Week
-7.86%
Perf Month
-14.94%
Perf Quarter
-17.66%
Perf Half Y
-28.09%
-
-
-
-
Beta
0.636
-
-
Volatility
0.45%, 1.03%
Prev Close
0.28%
Price
14.41
Change
2.56%
002317.SZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.93 | 3.15 | 2.36 | 3.05 | 3.32 | |
| Net income per share | 0.54 | 0.4 | -0.54 | 0.35 | 0.4 | |
| Operating cash flow per share | 0.41 | 0.31 | 0.17 | 0.78 | 0.08 | |
| Free cash flow per share | 0.23 | 0.15 | -0.02 | 0.51 | -0.25 | |
| Cash per share | 1.1 | 0.98 | 2.03 | 1.58 | 1.58 | |
| Book value per share | 4.84 | 5.06 | 4.39 | 4.36 | 4.6 | |
| Tangible book value per share | 2.48 | 2.77 | 3.53 | 3.37 | 3.48 | |
| Share holders equity per share | 4.84 | 5.06 | 4.39 | 4.36 | 4.6 | |
| Interest debt per share | 1.08 | 1.17 | 0.94 | 0.74 | 1.21 | |
| Market cap | 6.25B | 10.2B | 8.85B | 9.64B | 21.73B | |
| Enterprise value | 6.15B | 10.28B | 8.25B | 9.14B | 21.7B | |
| P/E ratio | 14.34 | 32.11 | -20.38 | 34.73 | 67.48 | |
| Price to sales ratio | 2.64 | 4.03 | 4.67 | 3.97 | 8.12 | |
| POCF ratio | 19.11 | 40.62 | 63.72 | 15.48 | 344.54 | |
| PFCF ratio | 34.07 | 83.07 | -571.08 | 23.57 | -106.06 | |
| P/B Ratio | 1.6 | 2.51 | 2.51 | 2.77 | 5.87 | |
| PTB ratio | 1.6 | 2.51 | 2.51 | 2.77 | 5.87 | |
| EV to sales | 2.61 | 4.06 | 4.35 | 3.76 | 8.11 | |
| Enterprise value over EBITDA | 9.77 | 16.65 | 16.94 | 16.95 | 40.15 | |
| EV to operating cash flow | 18.83 | 40.92 | 59.35 | 14.68 | 344.14 | |
| EV to free cash flow | 33.57 | 83.67 | -531.88 | 22.35 | -105.93 | |
| Earnings yield | 0.07 | 0.03 | -0.05 | 0.03 | 0.01 | |
| Free cash flow yield | 0.03 | 0.01 | 0 | 0.04 | -0.01 | |
| Debt to equity | 0.21 | 0.22 | 0.2 | 0.15 | 0.24 | |
| Debt to assets | 0.16 | 0.16 | 0.15 | 0.11 | 0.16 | |
| Net debt to EBITDA | -0.15 | 0.12 | -1.25 | -0.93 | -0.05 | |
| Current ratio | 2.69 | 2.52 | 3.82 | 5.1 | 2.92 | |
| Interest coverage | 14.71 | 10.76 | 10.43 | 6.01 | 5.1 | |
| Income quality | 0.76 | 0.79 | -0.32 | 2.27 | 0.2 | |
| Dividend Yield | 0.03 | 0.02 | 0.02 | 0.02 | 0.01 | |
| Payout ratio | 0.41 | 0.65 | -0.45 | 0.67 | 0.56 | |
| Sales general and administrative to revenue | 0.02 | 0.02 | 0.03 | 0.02 | 0.02 | |
| Research and developement to revenue | 0.04 | 0.05 | 0.06 | 0.06 | 0.06 | |
| Intangibles to total assets | 0.37 | 0.35 | 0.17 | 0.17 | 0.18 | |
| Capex to operating cash flow | -0.44 | -0.51 | -1.11 | -0.34 | -4.25 | |
| Capex to revenue | -0.06 | -0.05 | -0.08 | -0.09 | -0.1 | |
| Capex to depreciation | -1.83 | -1.31 | -1.57 | -2.23 | -2.69 | |
| Stock based compensation to revenue | 0 | 0.01 | -0.03 | 0.01 | 0 | |
| Graham number | 7.67 | 6.71 | 7.31 | 5.84 | 6.43 | |
| ROIC | 0.09 | 0.09 | 0.11 | 0.1 | 0.07 | |
| Return on tangible assets | 0.13 | 0.09 | -0.11 | 0.07 | 0.07 | |
| Graham Net | 0.74 | 0.73 | 1.83 | 0.99 | 0.67 | |
| Working capital | 1.51B | 1.63B | 2.31B | 2.15B | 2.13B | |
| Tangible asset value | 2B | 2.23B | 2.83B | 2.69B | 2.8B | |
| Net current asset value | 1.1B | 1.33B | 1.98B | 1.31B | 1.28B | |
| Invested capital | 0.21 | 0.22 | 0.2 | 0.15 | 0.24 | |
| Average receivables | 1.06B | 1.23B | 1.19B | 974.89M | 1.11B | |
| Average payables | 107.25M | 94.24M | 88.85M | 97.74M | 116.49M | |
| Average inventory | 277.24M | 329.68M | 388.88M | 428.02M | 466.63M | |
| Days sales outstanding | 177.48 | 189.68 | 203.17 | 134.41 | 179.45 | |
| Days payables outstanding | 40.2 | 35.38 | 49.31 | 48.28 | 49.01 | |
| Days of inventory on hand | 115.26 | 148.76 | 224.3 | 204.64 | 186.7 | |
| Receivables turnover | 2.06 | 1.92 | 1.8 | 2.72 | 2.03 | |
| Payables turnover | 9.08 | 10.32 | 7.4 | 7.56 | 7.45 | |
| Inventory turnover | 3.17 | 2.45 | 1.63 | 1.78 | 1.96 | |
| ROE | 0.11 | 0.08 | -0.12 | 0.08 | 0.09 | |
| Capex per share | -0.18 | -0.16 | -0.19 | -0.27 | -0.33 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.84 | 0.85 | 0.92 | 0.87 | 0.68 | |
| Net income per share | 0.06 | 0.09 | 0.17 | 0.08 | 0.08 | |
| Operating cash flow per share | 0.06 | 0.09 | 0.17 | 0.25 | -0.01 | |
| Free cash flow per share | -0.02 | -0.07 | 0.03 | 0.13 | -0.1 | |
| Cash per share | 1.98 | 1.57 | 1.57 | 2.09 | 2.28 | |
| Book value per share | 4.6 | 4.58 | 4.69 | 5.08 | 5.08 | |
| Tangible book value per share | 3.55 | 3.46 | 3.54 | 3.98 | 3.98 | |
| Share holders equity per share | 4.6 | 4.58 | 4.69 | 5.08 | 5.08 | |
| Interest debt per share | 1.5 | 1.1 | 0.75 | 0.64 | 0.83 | |
| Market cap | 10.37B | 21.83B | 16.61B | 14.4B | 16.12B | |
| Enterprise value | 10.28B | 21.81B | 16.17B | 13.34B | 15.21B | |
| P/E ratio | 55.76 | 74.44 | 29.8 | 52.06 | 56.8 | |
| Price to sales ratio | 15.59 | 31.87 | 22.25 | 19.58 | 27.36 | |
| POCF ratio | 223.03 | 297.76 | 119.21 | 68.84 | -2.09K | |
| PFCF ratio | -770.49 | -362.76 | 698.3 | 133.84 | -195.95 | |
| P/B Ratio | 2.86 | 5.9 | 4.38 | 3.34 | 3.68 | |
| PTB ratio | 2.86 | 5.9 | 4.38 | 3.34 | 3.68 | |
| EV to sales | 15.46 | 31.84 | 21.65 | 18.14 | 25.82 | |
| Enterprise value over EBITDA | 83.78 | 525.54 | 99 | 105.18 | 157.62 | |
| EV to operating cash flow | 221.17 | 297.42 | 116.01 | 63.74 | -1.97K | |
| EV to free cash flow | -764.06 | -362.33 | 679.58 | 123.94 | -184.88 | |
| Earnings yield | 0 | 0 | 0.01 | 0 | 0 | |
| Free cash flow yield | 0 | 0 | 0 | 0.01 | -0.01 | |
| Debt to equity | 0.32 | 0.24 | 0.16 | 0.12 | 0.16 | |
| Debt to assets | 0.2 | 0.16 | 0.1 | 0.08 | 0.11 | |
| Net debt to EBITDA | -0.7 | -0.61 | -2.73 | -8.41 | -9.44 | |
| Current ratio | 2.76 | 2.92 | 3.37 | 4.55 | 4.31 | |
| Interest coverage | 2.84 | -9.36 | 16.38 | 5.41 | 6.82 | |
| Income quality | 1 | 1 | 1 | 3.03 | -0.11 | |
| Dividend Yield | 0 | 0 | 0 | 0.01 | 0 | |
| Payout ratio | 0.11 | 0.06 | 0.02 | 2.37 | 0.03 | |
| Sales general and administrative to revenue | 0.14 | -0.11 | 0.05 | -0.03 | 0.16 | |
| Research and developement to revenue | 0.05 | 0.1 | 0.04 | 0.04 | 0.05 | |
| Intangibles to total assets | 0.15 | 0.18 | 0.19 | 0.18 | 0.18 | |
| Capex to operating cash flow | -1.29 | -1.82 | -0.83 | -0.49 | 9.65 | |
| Capex to revenue | -0.09 | -0.19 | -0.15 | -0.14 | -0.13 | |
| Capex to depreciation | -2.38 | -5.3 | -3.9 | -3.43 | 1.34 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0.02 | -0.03 | |
| Graham number | 2.47 | 3.06 | 4.27 | 3.05 | 3.07 | |
| ROIC | 0.02 | 0.02 | 0.03 | 0.02 | 0.01 | |
| Return on tangible assets | 0.01 | 0.02 | 0.03 | 0.01 | 0.01 | |
| Graham Net | 0.71 | 0.66 | 0.99 | 1.42 | 1.44 | |
| Working capital | 2.14B | 2.13B | 2.36B | 3.01B | 3.1B | |
| Tangible asset value | 2.8B | 2.8B | 2.87B | 3.37B | 3.43B | |
| Net current asset value | 1.23B | 1.28B | 1.58B | 2.13B | 2.17B | |
| Invested capital | 0.32 | 0.24 | 0.16 | 0.12 | 0.16 | |
| Average receivables | 1.11B | 1.25B | 1.37B | 1.31B | 1.18B | |
| Average payables | 107.43M | 118.5M | 126.63M | 123.07M | 110.06M | |
| Average inventory | 445.7M | 465.29M | 481.88M | 509.45M | 539.04M | |
| Days sales outstanding | 160.02 | 172.88 | 172.25 | 146 | 176.78 | |
| Days payables outstanding | 44.25 | 42.73 | 39.74 | 38.27 | 35.98 | |
| Days of inventory on hand | 179.66 | 162.79 | 151.05 | 172.2 | 193.07 | |
| Receivables turnover | 0.56 | 0.52 | 0.52 | 0.62 | 0.51 | |
| Payables turnover | 2.03 | 2.11 | 2.26 | 2.35 | 2.5 | |
| Inventory turnover | 0.5 | 0.55 | 0.6 | 0.52 | 0.47 | |
| ROE | 0.01 | 0.02 | 0.04 | 0.02 | 0.02 | |
| Capex per share | -0.08 | -0.17 | -0.14 | -0.12 | -0.09 |
002317.SZ Frequently Asked Questions
What is Guangdong Zhongsheng Pharmaceutical Co., Ltd. stock symbol ?
Guangdong Zhongsheng Pharmaceutical Co., Ltd. is a CN stock and trading under the symbol 002317.SZ
What is Guangdong Zhongsheng Pharmaceutical Co., Ltd. stock quote today ?
Guangdong Zhongsheng Pharmaceutical Co., Ltd. stock price is $14.41 today.
Is Guangdong Zhongsheng Pharmaceutical Co., Ltd. stock public?
Yes, Guangdong Zhongsheng Pharmaceutical Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 31.57M
- Market Capitalization 13.07B
- Employee 1.64K
- CEO Mr. Yong Hong Chen
- Headquarters Dongguan,CN
- IPO Date 2009-12-11
-
Website
https://www.zspcl.com 
Guangdong Zhongsheng Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. The company offers Chinese and chemical medicines. It is also involved in the research and development of products in the fields of ophthalmology, cardiovascular, cerebrovascular, respiratory, digestive, diabetes, tumor, and senile degenerative diseases. The company was founded in 1979 and is based in Dongguan, China.
